

LISTING OF THE CLAIMS

A listing of the claims and their current status is provided below for reference.

1.-47. (Canceled).

48. (Previously Presented) A method for providing analgesia in a subject, said method comprising systemically administering a composition comprising sufentanil to the subject, wherein the sufentanil is present in the composition at a concentration of about 0.5 mg/ml to about 500 mg/ml, and further wherein the composition is administered to the subject using an implantable convective delivery system, is delivered from the system for 48 hours or more at a low volume rate of from about 0.01 μ l/day to about 2 ml/day and is sufficient to provide analgesia in the subject.

49. (Previously Presented) The method of claim 48, wherein the composition is delivered using a patterned delivery regime.

50. (Previously Presented) The method of claim 49, wherein the composition is delivered in a substantially continuous fashion.

51. (Previously Presented) The method of claim 49, wherein the composition is delivered in a substantially uninterrupted manner for a pre-selected period of time.

52. (Previously Presented) The method of claim 49, wherein the composition is delivered in a substantially constant fashion.

53. (Previously Presented) The method of claim 49, wherein the composition is delivered over an extended period of time.

54. (Previously Presented) The method of claim 53, wherein the composition is delivered for a period of about 72 hours.

55. (Previously Presented) The method of claim 53, wherein the composition is delivered for a period from 2 to 5 days.

56. (Previously Presented) The method of claim 53, wherein the composition is delivered for a period of at least 100 days.

57. (Canceled).

58. (Previously Presented) The method of claim 49, wherein the implantable convective delivery system is implanted in the subject's body.

59. (Previously Presented) The method of claim 48, wherein the composition is delivered to the subject at a volume rate of from about 0.01 $\mu\text{l/day}$ to about 100 $\mu\text{l/day}$.

60. (Previously Presented) The method of claim 48, wherein the composition is delivered to the subject at a volume rate of from about 0.04 $\mu\text{l/day}$ to about 10 $\mu\text{l/day}$.

61. (Previously Presented) The method of claim 48, wherein the composition is delivered to the subject at a volume rate of from about 0.2 $\mu\text{l/day}$ to about 5 $\mu\text{l/day}$.

62. (Previously Presented) The method of claim 48, wherein the composition is delivered to the subject at a volume rate of from about 0.5 $\mu\text{l/day}$ to about 1 $\mu\text{l/day}$.

63. (Previously Presented) A method for providing analgesia in a subject, said method comprising systemically administering to the subject a composition comprising sufentanil, wherein said sufentanil is present in the composition at a concentration of about 0.5 mg/ml to about 500 mg/ml, and further wherein the composition is administered to the subject using an implantable convective delivery system, is delivered from the system at a low volume rate of from about 0.01 $\mu\text{l/day}$ to about 2 ml/day and is sufficient to provide analgesia in the subject.

64. (Previously Presented) The method of claim 63, wherein the sufentanil is in solution.

65. (Previously Presented) The method of claim 64, wherein the sufentanil is dissolved in a liquid carrier.

66. (Previously Presented) The method of claim 63, wherein the composition is administered to the subject as a semi-solid, gel, liquid, suspension, emulsion or an osmotic dosage pharmaceutical formulation.

67. (Previously Presented) The method of claim 63, wherein the sufentanil is present in the composition at a concentration of about 2 to about 10,000 times greater than the solubility of sufentanil in aqueous solution.

68. (Canceled).

69. (Previously Presented) The method of claim 63, wherein the sufentanil is present in the composition at a concentration of from about 1 mg/ml to about 400 mg/ml.

70. (Previously Presented) The method of claim 63, wherein the sufentanil is present in the composition at a concentration of from about 50 mg/ml to about 400 mg/ml.

71. (Previously Presented) The method of claim 63, wherein the sufentanil is present in the composition at a concentration of from about 75 mg/ml to about 300 mg/ml.

72. (Previously Presented) The method of claim 63, wherein the sufentanil is present in the composition at a concentration of from about 100 mg/ml to about 250 mg/ml.

73. (Canceled).

74. (Previously Presented) The method of claim 63, wherein the composition is delivered using a patterned delivery regime.

75. (Previously Presented) The method of claim 74, wherein the composition is delivered in a substantially continuous fashion.

76. (Previously Presented) The method of claim 74, wherein the composition is delivered in a substantially uninterrupted manner for a pre-selected period of time.

77. (Previously Presented) The method of claim 74, wherein the composition is delivered in a substantially constant fashion.

78. (Previously Presented) The method of claim 74, wherein the composition is delivered over an extended period of time.

79. (Previously Presented) The method of claim 78, wherein the composition is delivered for a period from about 2 to about 48 hours.

80. (Previously Presented) The method of claim 78, wherein the composition is delivered for a period from about 2 to 5 days.

81. (Previously Presented) The method of claim 78, wherein the composition is delivered for a period of at least about 100 days.

82. (Canceled).

83. (Previously Presented) The method of claim 74, wherein the implantable convective delivery system is implanted in the subject's body.

84. (Previously Presented) A method for providing analgesia in a subject, said method comprising systemically administering to the subject a composition comprising sufentanil, wherein the composition is administered to the subject using an implantable convective delivery system, the composition is delivered from the system for 48 hours or more at a low volume rate from about 0.1 μ l/day to about 2ml/day and is sufficient to deliver from about 0.01 μ g/hour to about 200 μ g/hour of the sufentanil to the subject, and further wherein said amount of delivered sufentanil is sufficient to establish a systemic analgesic effect in the subject.

85. (Previously Presented) The method of claim 84, wherein the sufentanil is in solution.

86. (Previously Presented) The method of claim 85, wherein the sufentanil is dissolved in a liquid carrier.

87. (Previously Presented) The method of claim 84, wherein the composition is administered to the subject as a semi-solid, gel, liquid, suspension, emulsion or an osmotic dosage pharmaceutical formulation.

88. (Previously Presented) The method of claim 84, wherein the systemic analgesic effect is sufficient to manage pain in the subject.

89. (Previously Presented) The method of claim 84, wherein the systemic analgesic effect is sufficient to treat pain in the subject.

90. (Previously Presented) The method of claim 84, wherein the systemic analgesic effect is sufficient to modulate pain response in the subject.

91. (Previously Presented) The method of claim 84, wherein the systemic analgesic effect is sufficient to ameliorate or alleviate pain in the subject.

92. – 99. (Canceled)